Rapidly Progressive Glomerulonephritis: Classification, Pathogenetic Mechanisms, and Therapy

https://doi.org/10.1016/S0272-6386(88)80079-9Get rights and content

Immunopathologic studies over the past two decades have demonstrated that rapidly progressive glomerulonephritis (RPGN) can result from glomerular deposition of anti-GBM antibody, immune complexes, or from some as yet undefined mechanism that does not involve glomerular antibody deposition. The latter process may be cell mediated and resembles a small vessel vasculitis. Most cases of idiopathic RPGN are not accompanied by pathogenic glomerular immunoglobulin deposition. Recent experimental studies of immune mechanisms of glomerular injury have identified several new processes that can induce damage to the capillary wall sufficient to result in crescentic glomerulonephritis (GN). These include direct effects of anti-GBM antibody alone and of the complement C5b-9 (membrane attack) complex, nephritogenic effects of inflammatory effector cells that involve reactive oxygen species and glomerular halogenation, and injury mediated by sensitized lymphocytes independently of antibody deposition. Macrophages have been shown to participate in both intracapillary and extracapillary fibrin deposition and crescent formation as well as to mediate capillary wall damage. The role of resident glomerular cells and cell-cell interactions in glomerulonephritis is still under active investigation. Despite these several advances in understanding immune injury to the glomerulus, therapy for RPGN remains largely empiric. Although the prognosis in RPGN has clearly improved over time, no form of disease-specific therapy has been clearly shown yet to be beneficial in a controlled study. Interpretation of the existing literature on therapy is complicated by the availability of only historical rather than concurrent controls, lack of attention to several variables known to affect disease outcome, and uncertainty regarding bias in favor of reporting positive results. Available data suggests that optimal outcomes may be achieved in anti-GBM nephritis by treatment with steroids, immunosuppression and plasma exchange, particularly when therapy is directed at patients with mild but rapidly progressive disease before oliguria or severe azotemia develop. Pulse steroids are probably the most cost-effective therapy for the idiopathic form of RPGN, but treatment with cytotoxic agents should be considered if clinical or histologic evidence of vasculitis is present.

Referencess (195)

  • AJ Rees et al.

    Strong association between HLA-DRW2 and antibody-mediated Goodpasture's syndrome

    Lancet

    (1978)
  • GA Muller et al.

    Association between rapidly progressive glomerulonephritis and the properdin factor BfF and different HLA-D region products

    Kidney Int

    (1984)
  • CE Alpers et al.

    Neoplasia and glomerular injury

    Kidney Int

    (1986)
  • K Min et al.

    The morphogenesis of glomerular crescents in rapidly progressive glomerulonephritis

    Kidney Int

    (1974)
  • NW Boyce et al.

    Direct anti-GBM antibody induced alterations in glomerular permselectivity

    Kidney Int

    (1986)
  • GC Groggel et al.

    Role of the terminal complement pathway in the heterologous phase of antiglomerular basement membrane nephritis in the rabbit

    Kidney Int

    (1985)
  • WG Couser et al.

    Complement and the direct mediation of immune glomerular injury: A new perspective (Editorial Review)

    Kidney Int

    (1985)
  • G Camussi

    Potential role of platelet-activating factor in renal pathophysiology

    Kidney Int

    (1986)
  • A Rehan et al.

    Role of oxygen radicals in phorbol myristate acetate-induced glomerular injury

    Kidney Int

    (1985)
  • RJ Johnson et al.

    Participation of the myeloperoxidase-(H202)-halide system in immune complex nephritis

    Kidney Int

    (1987)
  • MCM Vissers et al.

    The effect of oxidants on neutrophil-mediated degradation of glomerular basement membrane collagen

    Biochem Biophys Acta

    (1986)
  • PG Tipping et al.

    T-lymphocyte participation in antigen-induced experimental glomerulonephritis

    Kidney Int

    (1985)
  • DH Lovett et al.

    Cell culture approaches to the analysis of glomerular inflammation

    Kidney Int

    (1986)
  • DH Lovett et al.

    Neutral proteinase activity produced in vitro by cells of the glomerular mesangium

    Kidney Int

    (1983)
  • SR Holdsworth et al.

    Differential effects of steroids on leukocyte-mediated glomerulonephritis in the rabbit

    Kidney Int

    (1984)
  • R Atkins et al.

    The macrophage in human rapidly progressive glomerulonephritis

    Lancet

    (1976)
  • P Mahieu et al.

    Detection of humoral and cell-mediated immunity to kidney basement membranes in human renal diseases

    Am J Med

    (1972)
  • WK Bolton

    The role of corticosteroids in nephritic syndromes: The case for aggressive use

  • J Whitworth et al.

    The significance of extracapillary proliferation: Clinicopathological review of 60 patients

    Nephron

    (1976)
  • G Beirne et al.

    Idiopathic crescentic glomerulonephritis

    Medicine

    (1977)
  • WG Couser

    Idiopathic rapidly progressive glomerulonephritis

    Am J Nephrol

    (1982)
  • RJ Glassock et al.

    Primary glomerular disease

  • F Volhard et al.

    Die Brightsche Nierenkrankheit

    (1914)
  • RW Steblay

    Glomerulonephritis induced in sheep by injections of heterologous glomerular basement membrane and Freund's complete adjuvant

    J Exp Med

    (1962)
  • R Lerner et al.

    The role of antiglomerular basement membrane antibody in the pathogenesis of human glomerulonephritis

    J Exp Med

    (1967)
  • R Bacani et al.

    Rapidly progressive (nonstreptococcal) glomerulonephritis

    Ann Intern Med

    (1968)
  • A Cohen et al.

    Crescentic glomerulonephritis: Immune v nonimmune mechanisms

    Am J Nephrol

    (1981)
  • I Stachura et al.

    Circulating and deposited immune complexes in patients with glomerular disease

    Immunopathologic correlations. Am J Pathol

    (1981)
  • CB Wilson et al.

    Renal response to immunological injury

  • J Klassen et al.

    Evolution of membranous nephropathy into anti-glomerular-basementmembrane glomerulonephritis

    N Engl J Med

    (1974)
  • A Moorthy et al.

    Progression from membranous glomerulopathy to antiglomerular basement membrane (GBM) antibody mediated crescentic nephritis

    Clin Nephrol

    (1976)
  • A Pasternack et al.

    Evidence of both anti-GBM and immune complex mediated pathogenesis in the initial phase of Goodpasture's syndrome

    Clin Nephrol

    (1978)
  • J Velosa et al.

    Immunopathology of the end stage kidney

    Immunoglobulin and complement component deposition in non-immune disease. Am J Pathol

    (1976)
  • A Serra et al.

    Vasculitis affecting the kidney: Presentation, histopathology and long-term outcome

    Q J Med

    (1984)
  • JC Jennette et al.

    A clinicopathologic comparison between antigranulocyte cytoplasmic autoantibody-positive idiopathic necrotizing and crescentic glomerulonephritis and arthritis-associated glomerulonephritis

    Kidney Int

    (1988)
  • WG Couser

    In situ formation of immune complexes and the role of complement activation in glomerulonephritis

  • WG Couser et al.

    Immunopathogenesis of glomerular capillary wall injury in nephrotic states

    Contemp Issues Nephrol

    (1982)
  • DN Churchill et al.

    Association between hydrocarbon exposure and glomerulonephritis

    An appraisal of the evidence. Nephron

    (1983)
  • Daniell WE, Rosenstock L, Couser WG: Occupational solvent exposure and glomerulonephritis: A case report and review of...
  • SA Sadjadi et al.

    Rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis during treatment with high-dosage D-penicillamine

    Am J Nephrol

    (1985)
  • Cited by (337)

    • Nonneoplastic Diseases of the Kidney

      2020, Urologic Surgical Pathology
    View all citing articles on Scopus
    View full text